Oxford Biodynamics (OBD) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Oct 2023 07:00 AM
RNS
Bupa UK to cover EpiSwitch® CiRT for customers
06 Oct 2023 05:44 PM
RNS
Director/PDMR Shareholding
03 Oct 2023 04:37 PM
RNS
Holding(s) in Company
03 Oct 2023 07:00 AM
RNS
OBD receives reimbursement code for PSE test
26 Sep 2023 07:00 AM
RNS
OBD launches 94% accurate PSE test in US and UK
07 Sep 2023 10:18 AM
RNS
Holding(s) in Company
01 Sep 2023 12:34 PM
RNS
Amendment: Director/PDMR Shareholding
01 Sep 2023 12:34 PM
RNS
Amendment: Director/PDMR Shareholding
31 Aug 2023 04:02 PM
RNS
Holding(s) in Company
25 Aug 2023 09:00 AM
RNS
Holding(s) in Company
22 Aug 2023 03:58 PM
RNS
Holding(s) in Company
22 Aug 2023 07:00 AM
RNS
Holding(s) in Company
22 Aug 2023 07:00 AM
RNS
Holding(s) in Company
18 Aug 2023 11:44 AM
RNS
Result of General Meeting
08 Aug 2023 04:00 PM
RNS
Holding(s) in Company
04 Aug 2023 07:00 AM
RNS
Results of PrimaryBid Offer
02 Aug 2023 07:00 AM
RNS
Result of Placing and Subscription
01 Aug 2023 04:55 PM
RNS
PrimaryBid Offer
01 Aug 2023 04:54 PM
RNS
Proposed Fundraising
30 May 2023 07:00 AM
RNS
Half-year Report
16 May 2023 07:00 AM
RNS
Notice of Interim Results and Investor Webinar
15 May 2023 07:00 AM
RNS
CiRT expanded validation for ICI immunotherapies
02 May 2023 07:00 AM
RNS
US PACT Award for prognosis test for IOrelated HPD
18 Apr 2023 07:00 AM
RNS
Director/PDMR Shareholding
05 Apr 2023 07:00 AM
RNS
Business update for PSE and CiRT tests
30 Mar 2023 01:04 PM
RNS
Result of AGM
23 Mar 2023 03:19 PM
RNS
Holding(s) in Company
22 Mar 2023 02:22 PM
RNS
Holding(s) in Company
15 Mar 2023 11:43 AM
RNS
AIM Rule 17 Schedule 2(g) Update
03 Mar 2023 04:33 PM
RNS
Publication of FY22 Annual Report
23 Feb 2023 10:36 AM
RNS
PDMR Dealing
06 Feb 2023 07:00 AM
RNS
OBD Prostate Screening EpiSwitch Blood Test Update
27 Jan 2023 02:36 PM
RNS
Director/PDMR Shareholding
24 Jan 2023 07:00 AM
RNS
Preliminary Results and Notice of AGM
21 Dec 2022 07:00 AM
RNS
Notice of FY22 Results and Investor Webinar
19 Dec 2022 07:00 AM
RNS
OBD in San Francisco for JPM Healthcare conf 2023
16 Dec 2022 07:00 AM
RNS
Initial assessment of EpiSwitch assay in ALS trial
14 Dec 2022 12:35 PM
RNS
Holding(s) in Company
14 Dec 2022 07:00 AM
RNS
Exercise period extension - existing share options
01 Dec 2022 02:14 PM
RNS
Holding(s) in Company
28 Nov 2022 07:00 AM
RNS
Holding(s) in Company
21 Nov 2022 07:00 AM
RNS
Discussion about EpiSwitch CiRT at Key Summit
18 Nov 2022 04:40 PM
RNS
Second Price Monitoring Extn
18 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
14 Nov 2022 11:10 AM
RNS
Director/PDMR Shareholding
09 Nov 2022 04:07 PM
RNS
Director/PDMR Shareholding
08 Nov 2022 01:57 PM
RNS
Holding(s) in Company
02 Nov 2022 12:37 PM
RNS
Holding(s) in Company
02 Nov 2022 12:35 PM
RNS
Holding(s) in Company
02 Nov 2022 12:33 PM
RNS
Holding(s) in Company

Oxford Biodynamics' international store for clinical smart tests and research kits based on pioneering EpiSwitch® 3D genomic technology.

OBD was spun out of Oxford University in 2007 to commercialize blood tests based on 3D Genomics research. OBD's tests are designed to help people make informed health decisions and reduce healthcare costs.

OBD share price launched at 162p in 2016.

UK 100

Latest directors dealings